OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO Pharma Limited

Post-Mkt 03-03 17:32:01 EST

1.70

-0.07

-3.95%

盘后1.70

+0.000.00%

16:10 EST

High1.74	Low1.65	Vol133.89K
Open1.72	D1 Closing1.77	Amplitude4.94%
Mkt Cap87.33M	Tradable Cap53.30M	Total Shares51.37M
T/O225.77K	T/O Rate0.43%	Tradable Shares31.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO Pharma Limited","latestPrice":1.7,"timestamp":1772571600000,"preClose":1.77,"halted":0,"volume":133885,"hourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.7,"latestTime":"16:10 EST","volume":139,"amount":236.29999999999998,"timestamp":1772572204715,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.039548022598870095,"floatShares":31353600,"shares":51370200,"eps":-0.1114,"marketStatus":"Post-Mkt","change":-0.07,"latestTime":"03-03 17:32:01 EST","open":1.72,"high":1.7399,"low":1.6524,"amount":225771.7517,"amplitude":0.049435,"askPrice":1.75,"askSize":19,"bidPrice":1.7,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.1114,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772586000000},"marketStatusCode":4,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":1.77,"postHourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.7,"latestTime":"16:10 EST","volume":139,"amount":236.29999999999998,"timestamp":1772572204715,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.551855},"requestUrl":"/m/hq/s/OKYO/tweets","defaultTab":"tweets","newsList":[{"id":"2613773543","title":"OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613773543","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613773543?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:29","pubTimestamp":1771864148,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On February 23, 2026, OKYO Pharma announced that an abstract detailing the firs...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-urcosimod-ncp-data-selected-for-presentation-at-arvo-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharmas-urcosimod-ncp-data-selected-for-presentation-at-arvo-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2613733290","title":"OKYO Pharma Abstract Earns Presentation Slot at ARVO 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733290","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733290?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:00","pubTimestamp":1771862413,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL4TphnS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","OKYO","LU2210149790.SGD","SG9999014021.USD","BK4585","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2613735951","title":"OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2613735951","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613735951?lang=en_us&edition=fundamental","pubTime":"2026-02-24 00:00","pubTimestamp":1771862400,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb.  23, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242801/0/en/OKYO-Abstract-Selected-for-Presentation-at-Premier-Global-Ophthalmology-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2612612962","title":"Piper Sandler Initiates Coverage on OKYO Pharma With Overweight Rating, $7 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612612962","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612612962?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:15","pubTimestamp":1771589733,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) has an average rating of Buy and mean price target of $8, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OKYO"],"gpt_icon":0},{"id":"2612529265","title":"OKYO Pharma Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2612529265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612529265?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:19","pubTimestamp":1771582740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 05:19 ET (10:19 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2612265913","title":"Okyo Pharma initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2612265913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612265913?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:12","pubTimestamp":1771582348,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin initiated coverage of Okyo Pharma (OKYO) with an Overweight rating and $7 price target The firm is positive on the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2611970384","title":"OKYO Pharma Announces Public Offering of Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970384","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611970384?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:01","pubTimestamp":1770930060,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb.  12, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237645/0/en/OKYO-Pharma-Announces-Public-Offering-of-Ordinary-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2610175959","title":"OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2610175959","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610175959?lang=en_us&edition=fundamental","pubTime":"2026-02-11 23:09","pubTimestamp":1770822540,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Feb.  11, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236441/0/en/OKYO-Pharma-Announces-Transition-of-At-The-Market-Equity-Offering-Facility-to-Leerink-Partners.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","BK4215","OKYO","EQR"],"gpt_icon":0},{"id":"2610313009","title":"OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2610313009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610313009?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:39","pubTimestamp":1770809955,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an announcement. On February 10, 2026, OKYO Pharma Ltd entered into a Sales Agreement with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-launches-50-million-at-the-market-share-offering-with-leerink-partners?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-launches-50-million-at-the-market-share-offering-with-leerink-partners?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2610628324","title":"OKYO Pharma ernennt Flavio Mantelli zum Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610628324","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610628324?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728428,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. hat die Ernennung von Dr. Flavio Mantelli, MD, PhD, zum Chief Medical Officer bekanntgegeben. Zuvor wurde bereits Robert Dempsey als neuer CEO des Unternehmens vorgestellt. Dr. Mantelli war mageblich an der Entwicklung und Zulassung von Oxervate beteiligt und wird künftig die klinische Entwicklung und Strategie des Unternehmens insbesondere im Bereich neuropathischer Hornhautschmerz leiten.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLbzZx1b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","BK4585","BK4588","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","SG9999014021.USD","SG9999014005.SGD","OKYO","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2607366027","title":"OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2607366027","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607366027?lang=en_us&edition=fundamental","pubTime":"2026-01-31 06:52","pubTimestamp":1769813577,"startTime":"0","endTime":"0","summary":"An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On January 30, 2026, OKYO Pharma reported interim results for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-advances-urcosimod-with-positive-interim-results-and-fda-alignment-on-phase-2b-3-ncp-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-advances-urcosimod-with-positive-interim-results-and-fda-alignment-on-phase-2b-3-ncp-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2607847022","title":"OKYO Pharma reports half-year cash on hand of USD 4.2 million, up 163%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607847022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607847022?lang=en_us&edition=fundamental","pubTime":"2026-01-31 06:16","pubTimestamp":1769811364,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. reported its interim results for the six months ended 30 September 2025. Total assets stood at USD 4.6 million for the period. Cash on hand amounted to USD 4.2 million. The company reported a total comprehensive loss of USD 3.0 million for the half-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 30, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL7jyKg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2607040604","title":"OKYO Pharma to Present Phase 2 Urcosimod Efficacy Data at 2026 ASCRS Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040604","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040604?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:30","pubTimestamp":1769790616,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. announced that results from its proof-of-concept Phase 2 study of urcosimod  for the treatment of neuropathic corneal pain have been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery  Annual Meeting. The abstract, titled \"Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study,\" will be presented on April 11, 2026, in Washington, DC. The company also confirmed plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod in the first half of 2026. Urcosimod has been granted fast track designation by the FDA for the treatment of neuropathic corneal pain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL71tBPc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","BK4139","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BKPKM429.USD","OKYO","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2606719077","title":"OKYO Pharma Announces Successful Type C Meeting with the FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719077","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719077?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:40","pubTimestamp":1769604000,"startTime":"0","endTime":"0","summary":"FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approachLONDON and NEW YORK, Jan.  28, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3227523/0/en/OKYO-Pharma-Announces-Successful-Type-C-Meeting-with-the-FDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","LU2237443465.HKD","SAP","LU0267386448.USD","CMC","IE00BKVL7J92.USD","LU0882574139.USD","LU2237443978.SGD","LU2237443895.HKD","LU2746668974.SGD","BK4585","LU2746668461.USD","BK4006","IE00BFXG1179.USD","BK4613","LU0170899867.USD","BK4139","LU2237443622.USD","LU0149725797.USD","LU0971096721.USD","BK4588","IE00BZ1G4Q59.USD","BK4023","LU2237443549.SGD","LU2237443382.USD","IE00BHPRN162.USD","BK4528","LU1363072403.SGD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2606163291","title":"FDA Authorizes Compassionate Use of Urcosimod for Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2606163291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606163291?lang=en_us&edition=fundamental","pubTime":"2026-01-26 14:51","pubTimestamp":1769410291,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. announced that the U.S. Food and Drug Administration  has authorized a single-patient expanded access  Investigational New Drug  application for the use of urcosimod  in a patient with neuropathic corneal pain. The application was submitted by Pedram Hamrah, MD, at the University of South Florida. Urcosimod is being provided under the FDA-authorized expanded access program to a patient with severe neuropathic corneal pain, a condition for which there are currently no FDA-approved treatments. OKYO Pharma also noted that urcosimod was granted the first IND to treat patients with neuropathic corneal pain and was awarded fast track designation by the FDA. The company plans to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod for neuropathic corneal pain this year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL6xZbQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4139","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","OKYO","LU0314104364.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD"],"gpt_icon":0},{"id":"2605026754","title":"Analysts’ Top Healthcare Picks: OKYO Pharma Limited Sponsored ADR (OKYO), vTv Therapeutics (VTVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605026754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605026754?lang=en_us&edition=fundamental","pubTime":"2026-01-24 01:21","pubTimestamp":1769188902,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OKYO Pharma Limited Sponsored ADR (OKYO – Research R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-okyo-pharma-limited-sponsored-adr-okyo-vtv-therapeutics-vtvt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-okyo-pharma-limited-sponsored-adr-okyo-vtv-therapeutics-vtvt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","VTVT","LU0128526141.USD","XLV","HCSG","BK4588","LU0029874061.USD","XBI","BK4581","BK4137","LABU","BK4139","OKYO"],"gpt_icon":0},{"id":"2605472066","title":"FDA Approves Compassionate Use Of Urcosimod (0.05%) For The Treatment Of Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2605472066","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605472066?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:13","pubTimestamp":1769170400,"startTime":"0","endTime":"0","summary":"Jan 23 (Reuters) - OKYO Pharma Ltd ::*FDA APPROVES COMPASSIONATE USE OF URCOSIMOD (0.05%) FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN*OKYO PHARMA LTD - TO INITIATE 120-PATIENT STUDY OF URCOSIMOD TO ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nRSDbxGg0t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2601885745","title":"OKYO Pharma Names Robert J. Dempsey as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885745","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885745?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614426,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. has appointed Robert J. Dempsey as Chief Executive Officer, effective immediately. Gary S. Jacob, Ph.D., will transition to Chief Development Officer and remain on the Board of Directors. The Board unanimously approved these changes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLFZVyH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","OKYO","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","BK4585","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2592169769","title":"OKYO Pharma to Ring the Opening Bell at Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2592169769","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592169769?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:00","pubTimestamp":1766145600,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Dec.  19, 2025  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/19/3208403/0/en/OKYO-Pharma-to-Ring-the-Opening-Bell-at-Nasdaq.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4213","BK4139","REI"],"gpt_icon":0},{"id":"2591664164","title":"OKYO Pharma Chairman Gabriele Cerrone Increases Stake with Additional Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2591664164","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591664164?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:30","pubTimestamp":1765805424,"startTime":"0","endTime":"0","summary":"OKYO Pharma Ltd. has announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, has acquired 24,551 ordinary shares of the company on NASDAQ. This purchase brings Cerrone's total holding to 10,516,297 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3rbhNV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","OKYO","BK4139","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":-0.1366},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.2203},{"period":"1year","weight":0.4049},{"period":"ytd","weight":-0.1449}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.016922},{"month":2,"riseRate":0.25,"avgChangeRate":-0.048425},{"month":3,"riseRate":0.75,"avgChangeRate":-0.020808},{"month":4,"riseRate":0.666667,"avgChangeRate":0.001581},{"month":5,"riseRate":0.666667,"avgChangeRate":0.132873},{"month":6,"riseRate":0.5,"avgChangeRate":-0.013367},{"month":7,"riseRate":1,"avgChangeRate":0.208942},{"month":8,"riseRate":0.5,"avgChangeRate":0.008913},{"month":9,"riseRate":0.25,"avgChangeRate":-0.093671},{"month":10,"riseRate":0.5,"avgChangeRate":0.07182},{"month":11,"riseRate":0,"avgChangeRate":-0.142327},{"month":12,"riseRate":0.75,"avgChangeRate":0.059341}],"exchange":"NASDAQ","name":"OKYO Pharma Limited","nameEN":"OKYO Pharma Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO Pharma Limited,OKYO,OKYO Pharma Limited股票,OKYO Pharma Limited股票老虎,OKYO Pharma Limited股票老虎国际,OKYO Pharma Limited行情,OKYO Pharma Limited股票行情,OKYO Pharma Limited股价,OKYO Pharma Limited股市,OKYO Pharma Limited股票价格,OKYO Pharma Limited股票交易,OKYO Pharma Limited股票购买,OKYO Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction